Only three types of drug-resistant bacteria make the Center for Disease Control and Prevention’s list of “urgent” threats. One of them is gonorrhea.
That particular sexually transmitted infection is the target of a new drug being developed by Entasis, an antibiotics-focused spin-off from pharma giant AstraZeneca (AZN). But they’re getting help: their nonprofit partner, the Global Antibiotic Research and Development Partnership, will be funding the next round of trials and doing studies to ensure this drug keeps working for as long as possible. The partnership is GARDP’s first.